Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Organisation › Details

Aqualis ASA

Clavis Pharma ASA is a late clinical stage oncology discovery and drug development company based in Oslo, Norway with a portfolio of novel anti-cancer drugs in development. These patented New Chemical Entities (NCEs) are novel, improved versions of commercially successful drugs, made using Clavis Pharma's Lipid Vector Technology (LVT) chemistry. Data generated suggests these potential breakthrough products may offer improved efficacy and reduced side effects through enhanced pharmacokinetic properties, greater tissue penetration, altered metabolism and, in certain cases, additional modes of action. Clavis Pharma's has several drug candidates in formal development studies: * Elacytarabine, a leukaemia drug, currently in a randomized, controlled Phase III study in late-stage acute myeloid leukaemia; * CP-4126, is currently in a pivotal clinical study compared to gemcitabine for the 1st line treatment of pancreatic cancer and a Phase II trial for 2nd line treatment for pancreatic cancer in patients refractory to 1st line gemcitabine treatment; * CP-4200, an azacitidine derivative, in preclinical development for myelodysplastic syndrome (MDS), a disease that is often a precursor to leukaemia. Clavis Pharma intends to commercialise its products through strategic alliances and partnerships with experienced oncology businesses and, where and when commercially appropriate, by establishing its own sales and marketing capabilities. *


Period Start 2013-10-09 renamed
  Predecessor Clavis Pharma ASA
Products Industry cancer drug
  Industry 2 Lipid Vector Technology (LVT)
Persons Person Hellebø, Olav (ReNeuron 201507 CEO before Clavis Pharma 201108 CEO)
  Person 2 Manum, Gunnar (Clavis Pharma 201107 CFO)
Region Region Oslo
  Country Norway
  City 0256 Oslo
    Address record changed: 2013-11-02
Basic data Employees n. a.
    * Document for �About Section�: Clavis Pharma ASA. (1/17/12). "Press Release: Clavis Pharma. Contemplated Private Placement of up to Approximately 2.85 Million New Shares". Oslo.
Record changed: 2017-04-01


Picture [iito] Männer Ballett 650x80px

More documents for Aqualis ASA

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top